OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th
OraSure Technologies (NASDAQ: OSUR) will report its third quarter 2026 financial results after the market closes on November 9, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OraSure Technologies (NASDAQ: OSUR) will report its third quarter 2026 financial results after the market closes on November 9, 2026. The company will host an earnings call at 5:00 p.m. Eastern Time that day. A webcast will be available through its investor relations website, with an archived recording available shortly afterward for approximately one year.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BETHLEHEM, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its third quarter 2026 financial results on Monday, November 9, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5:00 p.m. Eastern Time on that day.
A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately one year.
About OraSure Technologies, Inc.
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com.
| Investor Contact: | Media Contact: |
| Mike Vallie | Amy Koch |
| investorinfo@orasure.com | media@orasure.com |
